Billionaire Family Office Acquires $65 Million of HeartFlow as Stock Jumps 70% From IPO

Schusterman Interests disclosed a new third-quarter 13F position in HeartFlow (HTFL), acquiring 1.9 million shares valued at $65.3 million as of Sept. 30, making HTFL its fourth-largest holding at 14.9% of the fund’s disclosed AUM. HeartFlow, which began trading in August after an IPO priced at $19, closed recently at $32.25 (roughly +70% from IPO); the company has a $2.7 billion market cap, $161.9M revenue (TTM) and a -$125.4M net loss (TTM). The filing signals a vote of confidence from a billionaire-backed family office in an AI-driven cardiology diagnostics platform, a development that may attract long-horizon investors though medtech valuations and early-stage revenue durability remain key risks.

Analysis

Market structure: Schusterman’s $65M stake and a ~70% post-IPO pop signal outsized institutional demand for AI-enabled diagnostics (HTFL market cap $2.7B, TTM revenue $162M). Direct beneficiaries are HeartFlow (software sales, recurring-use potential) and imaging analytics vendors; losers are incremental-use-driven cath-lab services and device vendors if non‑invasive testing displaces a portion of angiography volumes. The immediate supply/demand imbalance is retail/institutional chase vs limited post-IPO float, keeping near-term volatility and option-implied vol elevated.

Risk assessment: Key tail risks are adverse CMS reimbursement rulings, FDA/coverage setbacks, or negative peer-reviewed outcome studies that could halve addressable demand; a failed reimbursement decision within 6–12 months would be material. Short-term (days–months) risk is a momentum unwind (20–40% pullback); long-term (years) execution risk centers on converting pilot accounts to recurring revenue and achieving margin expansion from current loss of $125M TTM. Hidden dependency: outsized reliance on payer coding and hospital IT integration slows scaling and raises sales/SG&A intensity.

Trade implications: For conviction buyers, size exposure conservatively (1–2% portfolio) and prefer defined-risk option structures because of elevated IV; consider 9–15 month call spreads (e.g., Jan 2026 HTFL 25/45 call spread) to capture commercialization upside while capping premium outlay. Relative-value: long HTFL vs short BSX (Boston Scientific) 0.5–1% to express share-shift risk from invasive to non-invasive cardiology over 12–36 months. Reduce standalone exposure to large cath-lab equipment makers by 1–2% and reallocate to AI diagnostics and imaging analytics.

Contrarian angles: The market underestimates reimbursement and clinical-adoption friction—HTFL trades at ~16.7x TTM revenue which presumes fast adoption and margin recovery; that may be overdone given sales intensity needed. If clinical outcomes and CMS coding track positively over the next 6–12 months, upside rerating could be 30–70%; conversely, a single negative coverage decision could compress value by >40%. Historical parallels: early-stage medtech IPOs that rose on story but later stalled without durable payer wins (e.g., several AI/diagnostics names), implying careful staged sizing and milestone-based scaling.

Key Decisions for Investors

• Establish a tactical long HTFL position sized 1–2% of net assets; stagger entries: initial 50% at market ($32–33), scale remainder on pullback to $26 (≈20% retrace) or on confirmed Medicare local coverage within 60–90 days.
• Use defined-risk options instead of naked buys: buy Jan 2026 HTFL 25/45 call spread (or equivalent) sized to target 1% portfolio exposure, max loss = premium; alternatively buy Jan 2026 30C and sell 45C if lower cost tolerated.
• Implement a pair trade: go long HTFL (0.75% portfolio) and short BSX (0.75%) to express share-shift risk; rebalance if HTFL adoption metrics (monthly case volumes, payer wins) exceed +30% YoY within 12 months.
• Reduce exposure to cath‑lab centric device names by 1–2% and redeploy into AI/diagnostic names if HeartFlow posts sequential revenue growth >25% YoY or demonstrates positive unit economics (contribution margin turning positive) within two quarters.
• Monitor three binary catalysts over next 90–180 days before increasing size: (1) CMS/NCD/LCD coverage decisions, (2) Q4 revenue/usage metrics vs consensus (target: >25% YoY growth), (3) new peer‑reviewed clinical outcomes showing non‑inferiority or superiority—add only after two positives.